Response to subsequent tyrosine kinase inhibitors after detection of F317L
| Regimen . | Mutation after imatinib therapy (n = 12, 12% of all patients with mutations) . | Mutation after dasatinib therapy (n = 8, 50% of all patients with mutations) . | ||||
|---|---|---|---|---|---|---|
| n . | Response . | Duration, mo . | n . | Response . | Duration, mo . | |
| Salvage 1 | ||||||
| High-dose imatinib | 2 | CCyR | 24+ | 0 | NA | NA |
| CCyR* | 26+ | |||||
| Dasatinib | 3 | PHR | 4 | 0 | NA | NA |
| CHR | 10 | |||||
| CHR | 12 | |||||
| Nilotinib | 4 | CHR | 15 | 1 | CCyR† | 4 |
| MMR* | 22 | |||||
| CMR | 30+ | |||||
| NR | NA | |||||
| Bosutinib | 0 | NA | NA | 1 | NR‡ | NA |
| Salvage 2 | ||||||
| Nilotinib | 1 | NR | NA | 0 | NA | NA |
| Bosutinib | 2 | CHR | 9 | 0 | NA | NA |
| CHR | 6 | |||||
| Regimen . | Mutation after imatinib therapy (n = 12, 12% of all patients with mutations) . | Mutation after dasatinib therapy (n = 8, 50% of all patients with mutations) . | ||||
|---|---|---|---|---|---|---|
| n . | Response . | Duration, mo . | n . | Response . | Duration, mo . | |
| Salvage 1 | ||||||
| High-dose imatinib | 2 | CCyR | 24+ | 0 | NA | NA |
| CCyR* | 26+ | |||||
| Dasatinib | 3 | PHR | 4 | 0 | NA | NA |
| CHR | 10 | |||||
| CHR | 12 | |||||
| Nilotinib | 4 | CHR | 15 | 1 | CCyR† | 4 |
| MMR* | 22 | |||||
| CMR | 30+ | |||||
| NR | NA | |||||
| Bosutinib | 0 | NA | NA | 1 | NR‡ | NA |
| Salvage 2 | ||||||
| Nilotinib | 1 | NR | NA | 0 | NA | NA |
| Bosutinib | 2 | CHR | 9 | 0 | NA | NA |
| CHR | 6 | |||||
CCyR indicates complete cytogenetic response; PHR, partial hematologic response; CHR, complete hematologic response; MMR, major molecular response; CMR, complete molecular response; NR, no response; and NA, not applicable.
Eradication of the F317L mutant clone.
Increase of the F317L mutant clone from 25% to 43%.
Decrease of the mutant clone from 70% to 3%.